Printer Friendly

GPC Biotech announces issuance of United States patent for detecting diseased cells.

GPC Biotech AG (Martinsried/Munich, Germany; 49 (0)89 8565-2691) a leading genomics- and proteomics-driven drug discovery and development company, announced that the United States Patent and Trademark Office has issued a patent (United States Patent 6,342,356) describing genetic approaches to elucidate molecular differences between normal and diseased cells that can be exploited for drug discovery. The methods and reagents covered in the patent allow GPC Biotech to identify validated drug targets in diseased cells. This technology provides the basis for identifying genes that are associated with the fundamental biological mechanisms of a disease.

The technology utilizes libraries of short antisense fragments of RNA to inhibit the function of individual genes and selects for those genes whose inhibition in the diseased cells provide the desired therapeutic effect (e.g. the induction of apoptosis (programmed cell death) in tumor cells, but not in normal cells).

"This patent further strengthens GPC Biotech's already strong patent position. Our integrated technology platform allows us to address the great need in the biopharmaceutical industry of generating high quality validated targets. We have already started commercializing this technology on a non-exclusive basis and plan to further partner it in pharmaceutical or biotech alliances," commented Jeno Gyuris, Ph.D., Vice President, Molecular Technologies of GPC Biotech.

GPC Biotech is a genomics- and proteomics-driven drug discovery company focused on applying a number of proprietary genomic, proteomic and drug discovery technologies to accelerate the identification and validation of novel drug targets for development of mechanism-based drugs in oncology, infectious diseases and immunology. GPC Biotech has leading cell cycle expertise and a broad intellectual property position. Drug discovery alliance partners include: the ALTANA AG pharmaceuticals group Byk Gulden, Aventis Pharma, Boehringer Ingelheim International, Cell Genesys and MorphoSys.
COPYRIGHT 2002 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Potential for drug discovery
Comment:GPC Biotech announces issuance of United States patent for detecting diseased cells.(Potential for drug discovery)
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:4EUGE
Date:Mar 1, 2002
Previous Article:Viragen granted interferon patent.
Next Article:U.S. Genomics awarded pioneering patent.

Related Articles
Biolog granted gene function patent.
Lexicon Genetics announces issuance of two key gene trapping patents.
Elitra announces issuance of patent on genome-wide shotgun antisense method.
Karo Bio patents estrogen receptor complex.
MorphoSys wins final ruling in patent dispute with CAT.
Lexicon patents gene trapping technology.
GPC Biotech licenses reverse genomics technology from ARIAD.
Lexicon extends intellectual property portfolio with patent on gene trapping.
Rigel granted patents in immunology, virology and oncology.
Patent for delivery of stem cells to human heart issued to CellCyte Genetics.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters